The FDA is moving toward easing restrictions on certain peptides by convening advisory panel discussions about whether compounding pharmacies should be allowed to make products that were previously restricted. The agency’s review aims to reconsider a framework around “untested” peptide injections and their safety risks. The update arrives as FDA communications and political attention keep focus on peptide use outside traditional drug development. In parallel, STAT also reported that the FDA is revisiting its stance, with meetings planned in coming months and before early 2027. For biotech and pharma, the immediate implication is that the regulatory boundary between compounded products and approved drugs may shift—affecting market dynamics for peptide-like therapeutics and the evidentiary expectations for safety and manufacturing.